Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment-Reference-Cited by-同舟云学术

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment

Published:2019-03-01 Issue:5 Volume:44 Page:619-628
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Eur J Drug Metab Pharmacokinet

Author:

Heinig Roland^ORCID,Lambelet Marc,Nagelschmitz Johannes,Alatrach Abir,Halabi Atef

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s13318-019-00547-x.pdf

Reference22 articles.

1. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65(2):257–63. https://doi.org/10.1161/HYPERTENSIONAHA.114.04488 .

2. Schwenk MH, Hirsch JS, Bomback AS. Aldosterone blockade in CKD: emphasis on pharmacology. Adv Chronic Kidney Dis. 2015;22(2):123–32. https://doi.org/10.1053/j.ackd.2014.08.003 .

3. Kolkhof P, Bärfacker L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125–40. https://doi.org/10.1530/JOE-16-0600 .

4. Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271–305. https://doi.org/10.1007/164_2016_76 .

5. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385–403. https://doi.org/10.1002/cmdc.201200081 .

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene expression analysis to identify mechanisms underlying improvement of myocardial fibrosis by finerenone in SHR;Biochemical Pharmacology;2024-02

2. The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone;Clinical Pharmacokinetics;2023-10-24

3. Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes;American Journal of Health-System Pharmacy;2023-08-26

4. Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review;Journal of Cardiovascular Development and Disease;2023-05-28

5. Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection;Current Problems in Cardiology;2022-12